Deerfield’s Private Designs
This article was originally published in Start Up
Executive Summary
Deerfield Management has a blank slate with its new $1.6 billion fund for health care investment, the third that it’s dedicated to private company investment and public company structured financing. The hedge fund is trying to reprise the performance of its prior two Private Design funds, for which it claims only one loss thus far in each.
You may also be interested in...
Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs
An alliance of Deerfield and the Broad Institute to accelerate research into high-mortality diseases identifies its first two research projects, while Janssen and UPenn look into gene therapy for Alzheimer's disease.
Kolltan Raises $60 Million Series D, But Keeps Mum About Cancer Program
Never a company known to offer much detail about its plans, Kolltan has raised a $60 million Series D led by an undisclosed global institutional asset manager. Its lead program is in Phase I with the biotech planning a Phase II program combining KTN3379 with other cancer therapies.
Deerfield Management Opts For More Private Investment And A New Public Face
Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.